ranolazine tablet 500 mg film coated extended release

1 INDICATIONS AND USAGE Ranolazine extended-release tablets are indicated for the treatment of chronic angina. Ranolazine extended-release tablets may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors and angiotensin receptor blockers. Ranolazine extended-release tablets are an antianginal indicated for the treatment of chronic angina. (1)

amneal pharmaceuticals llc

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] rheumatoid arthritis` `[3] pain` `[4] drug intolerance` `[5] fatigue` `[6] arthralgia` `[7] joint swelling` `[8] off label use` `[9] rash` `[10] abdominal discomfort`

4 years ago

OVAL ORANGE AN376

16 HOW SUPPLIED/STORAGE AND HANDLING

RANOLAZINE extended-release tablets, 500 mg , are supplied as light orange, oblong shaped, film-coated, unscored tablets, debossed with “AN376” on one side and plain on the other side. They are available as follows: Bottles of 60: NDC: 65162-376-06 Bottles of 180: NDC: 65162-376-18 Bottles of 500: NDC: 65162-376-50

RANOLAZINE extended-release tablets, 1000 mg , are supplied as pale yellow, oblong shaped, film-coated, unscored tablets, debossed with “AN379” on one side and plain on the other side. They are available as follows: Bottles of 60: NDC: 65162-379-06 Bottles of 180: NDC: 65162-379-18 Bottles of 500: NDC: 65162-379-50 Store

RANOLAZINE extended-release tablets at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP controlled Room Temperature].

More pills like OVAL AN376

Related Pills

ranolazine tablet 1000 mg film coated extended release

amneal pharmaceuticals llc

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site